Supply of buprenorphine waivered physicians: The influence of state policies

Journal of Substance Abuse Treatment

Volumn 48, Issue 1, 2015, Pages 104-111

  Stein, Bradley D ^a,b   Gordon, Adam J ^b,c   Dick, Andrew W ^a   Burns, Rachel M ^a   Pacula, Rosalie Liccardo ^a   Farmer, Carrie M ^a   Leslie, Douglas L ^d   Sorbero, Mark ^a  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Buprenorphine; Medicaid; Medication assisted treatment; Opioid use disorder; State policy

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE; NARCOTIC ANALGESIC AGENT;

ARTICLE; BUPRENORPHINE WAIVERED PHYSICIAN; DRUG OVERDOSE; DRUG USE; FUNDING; HEALTH CARE PERSONNEL MANAGEMENT; HEALTH CARE POLICY; HOSPITAL POLICY; HUMAN; MEDICAID; OPIATE ADDICTION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RESIDENT; UNITED STATES; LEGISLATION AND JURISPRUDENCE; OPIATE SUBSTITUTION TREATMENT; POLICY; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; BUPRENORPHINE; DRUG PRESCRIPTIONS; HUMANS; MEDICAID; METHADONE; OPIATE SUBSTITUTION TREATMENT; PHYSICIANS; PUBLIC POLICY; UNITED STATES;

EID: 84922830146     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.07.010     Document Type: Article

References (77)

1. American Methadone Treatment Association Methadone maintenance program and patient census in the US 1998, American Methadone Treatment Association, New York.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV) 1994, American Psychiatric Press, Inc., Washington, D.C.
3. American Psychiatric Association DSM V: American Psychiatric Association 2013.
4. Arfken C.L., Johanson C.E., di Menza S., Schuster C.R. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. Journal of Substance Abuse Treatment 2010, 39(2):96-104.
5. Arkes J., Pacula R.L., Paddock S., Caulkins J., Reuter P. Technical Report for the Price and Purity of Illicit Drugs Through 2003. Office of National Drug Control Policy November; 2004 2004.
6. Arkes J., Pacula R.L., Paddock S., Caulkins J., Reuter P. Why the DEA Stride data are still useful for understanding drug markets. National Bureau of Economic Research 2008.
7. Ball J., Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome 1991, Springer-Verlag, New York.
8. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104(6):982-992.
9. Barnett P.G., Zaric G.S., Brandeau M.L. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001, 96(9):1267-1278.
10. Baxter J.D., Clark R.E., Samnaliev M., Leung G.Y., Hashemi L. Factors associated with Medicaid patients' access to buprenorphine treatment. Journal of Substance Abuse Treatment 2011, 41:88-96.
11. Bell J., Dru A., Fischer B., Levit S., Sarfraz M.A. Substitution therapy for heroin addiction. Substance Use & Misuse 2002, 37(8-10):1149-1178.
12. Carpenter B.E., Neun S.P. An analysis of the location decision of young primary care physicians. Atlantic Economic Journal 1999, 27(2):135-149.
13. Caulkins J., Pacula R., Arkes J., Reuter P., Paddock S., Iguchi M., et al. The price and purity of illicit drugs: 1981 through the second quarter of 2003, Office of National Drug Control Policy 2004.
14. Center for Substance Abuse Treatment Clinical guidelines for the use of buprenorphine treatment of opioid addiction Treatment Improvement Protocol (TIP) Series 40 2004, Substance Abuse and Mental Health Services Administration, Rockville, MD.
15. Center for Substance Abuse Treatment State Systems Technical Assistance Project Implementing medication-assisted treatment statewide white paper (SAMHSA, trans.) 2010, 62.
16. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services The Determinations Report: A Report On the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 ("DATA") 2006, (Rockville, MD).
17. Centers for Disease Control and Prevention National Vital Statistics System 2010 Multiple cause of death file 2012, US Department of Health and Human Services, Hyattsville, MD.
18. Clark R.E., Samnaliev M., Baxter J.D., Leung G.Y. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs 2011, 30(8):1425-1433.
19. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment 2007, 11(9):1-171. (iii-iv).
20. Cooper R.A., Getzen T.E., McKee H.J., Laud P. Economic and demographic trends signal an impending physician shortage. Health Affairs 2002, 21(1):140-154.
21. Cunningham C., Kunins H., Roose R., Elam R., Sohler N. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. Journal of General Internal Medicine 2007, 22(9):1325-1329.
22. Cunningham P.J., O'Malley A.S. Do reimbursement delays discourage Medicaid participation by physicians?. Health Affairs 2009, 28(1):w17-w28.
23. Damschroder L.J., Hagedorn H.J. A guiding framework and approach for implementation research in substance use disorders treatment. Psychology of Addictive Behaviors 2011, 25(2):194-205.
24. Department of Health and Human Services, U.S., Resources and Services Administration The physician workforce: Projections and research into current issues affecting supply and demand 2008.
25. Doran C.M., Shanahan M., Mattick R.P., Ali R., White J., Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug and Alcohol Dependence 2003, 71(3):295-302.
26. Ducharme L., Abraham A. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 2008, 3(1):17-27.
27. Fiellin D.A. The first three years of buprenorphine in the United States: experience to date and future directions. Journal of Addiction Medicine 2007, 1(2):62-67.
28. Fiellin D.A., O'Connor P.G. Clinical practice. Office-based treatment of opioid-dependent patients. New England Journal of Medicine 2002, 347(11):817-823.
29. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine 2006, 355(4):365-374.
30. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003, 349(10):949-958.
31. Gifford K. A profile of Medicaid managed care programs in 2010: Findings from a 50-state survey 2011, Henry J. Kaiser Family Foundation.
32. Gordon A.J., Fiellin D.A., Friedmann P.D., Gourevitch M.N., Kraemer K.L., Arnsten J.H., et al. Update in addiction medicine for the primary care clinician. Journal of General Internal Medicine 2008, 23(12):2112-2116.
33. Gordon A.J., Kavanagh G., Krumm M., Ramgopal R., Paidisetty S., Aghevli M., et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of Addictive Behaviors 2011, 25(2):215-224.
34. Gordon A.J., Liberto J., Granda S., Salmon-Cox S., Andrée T., McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. American Journal on Addictions 2008, 17(6):459-462.
35. Gordon A.J., Liberto J., Granda S., Salmon-Cox S., Andrée T., McNicholas L. Physician training is never a failure. American Journal on Addictions 2009, 18(4):337-338.
36. Gordon A.J., Trafton J.A., Saxon A.J., Gifford A.L., Goodman F., Calabrese V.S., et al. Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3years. Drug and Alcohol Dependence 2007, 90(2-3):292-296.
37. Hargraves J.L., Hadley J. The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. Health Services Research 2003, 38(3):809-829.
38. Harris A.H., Gospodarevskaya E., Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. PharmacoEconomics 2005, 23(1):77-91.
39. Hayes B.D., Klein-Schwartz W., Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics 2008, 121(4):e782-e786.
40. Hobbs E., Freese T., Laurie K. Addressing resistance to medication-assisted treatment. Paper presented at the American Association for the Treatment of Opioid Dependence 2012 National Conference, Las Vegas, NV 2012, (http://www.slideshare.net/ATTCNetwork/attc-networks-efforts-to-address-resistance-to-medicationassisted-treatment).
41. Jin M., Naumann T., Regier L., Bugden S., Allen M., Salach L., et al. A brief overview of academic detailing in Canada: Another role for pharmacists. Canadian Pharmacists Journal 2012, 145(3):142-146. (e142).
42. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 2000, 343(18):1290-1297.
43. Jones E.S., Moore B.A., Sindelar J.L., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug and Alcohol Dependence 2009, 99(1-3):132-140.
44. Kakko J., Svanborg K.D., Kreek M.J., Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361(9358):662-668.
45. Koch A.L., Arfken C.L., Schuster C.R. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence 2006, 83:274-278.
46. Ling W., Jacobs P., Hillhouse M., Hasson A., Thomas C., Freese T., et al. From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. Journal of Substance Abuse Treatment 2010, 38:S53-S60.
47. Litaker D., Koroukian S.M., Love T.E. Context and healthcare access: looking beyond the individual. Medical Care 2005, 43(6):531-540.
48. Litaker D., Love T.E. Health care resource allocation and individuals' health care needs: examining the degree of fit. Health Policy 2005, 73(2):183-193.
49. Magellan Health Services Magellan's integrated substance use solutions 2013, (Retrieved June 18, 2013, from https://http://www.magellanprovider.com/MHS/MGL/providing_care/clinical_guidelines/MISUS/index.asp).
50. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, (3):CD002209.
51. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, (2).
52. Megarbane B., Buisine A., Jacobs F., Resiere D., Chevillard L., Vicaut E., et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. Journal of Substance Abuse Treatment 2010, 38(4):403-407.
53. National Consensus Development Panel Effective medical treatment of opiate addiction. Journal of the American Medical Association 1998, 280(22):1936-1943.
54. National Institute of Drug Abuse Principles of effective treatment for criminal justice populations. Rockville, MD 2006.
55. National Institute of Drug Abuse National Quality Forum Evidence-based treatment practices for substance use disorders: Workshop proceedings National Quality Forum. Washington, D.C. 2005.
56. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E.G., Carroll K.M., Kosten T.R., et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine 1998, 105(2):100-105.
57. Oliva E.M., Maisel N.C., Gordon A.J., Harris A.H. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current Psychiatry Reports 2011, 13(5):374-381.
58. PCSS-O Prescribers' clinical support system for opioid therapies training 2013, (Retrieved June 18, 2013, from http://www.pcss-o.org/).
59. Phelps C. Chapter 7: physicians in the marketplace. Physician location decisions health economics 2009, Pearson. 4th ed.
60. Phelps C.E. Health economics 2012, Prentice Hall. 5th ed.
61. Rinaldo D. 50-State Table: Medicaid financing of medication-assisted treatment for opiate addiction 2008, (Retrieved January 7, 2011, from http://www.ncsl.org/Default.aspx?TabId=14144).
62. Rinaldo S.G., Rinaldo D.W. Availability without accessability? State Medicaid covereage and authorization requirements for opioid dependence medications 2013, The AVISA Group.
63. Roman P.M., Abraham A.J., Knudsen H.K. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addictive Behaviors 2011, 36(6):584-589.
64. SAMHSA Treatment Episode Data Sets (TEDS): 1997-2007. National admissions to substance abuse treatment services DASIS Series: S-47 2009, DHHS, Rockville, MD.
65. SAMHSA Uninsured employed admissions to treatment 2010, (Retrieved June 21, 2013, from http://www.samhsa.gov/data/2k10/223/223FTEmpUnisrd2k10.htm).
66. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. Journal of the American Medical Association 2000, 283(10):1303-1310.
67. Soumerai S.B. Principles and uses of academic detailing to improve the management of psychiatric disorders. International Journal of Psychiatry in Medicine 1998, 28(1):81-96.
68. Stein B.D., Gordon A.J., Sorbero M., Dick A.W., Schuster J., Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug and Alcohol Dependence 2012, 123(1-3):72-78.
69. Substance Abuse and Mental Health Services Administration National Survey of Substance Abuse Treatment Services (N-SSATS): 2011. Data on substance abuse treatment facilities 2012, Substance Abuse and Mental Health Services Administration, Rockville, MD.
70. Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality The NSDUH report: state estimates of nonmedical use of prescription pain relievers 2013, Rockville, MD; 2013.
71. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?. Drug and Alcohol Dependence 2005, 79(1):113-116.
72. The Kaiser Commission on Medicaid and the Uninsured Medicaid managed care: Key data, trends, and issues 2012, The Henry J. Kaiser Family Foundation, Washington, DC.
73. U.S. Department of Health and Human Services, & Substance Abuse and Mental Health Services Administration Office of Applied Studies Results from the 2009 National Survey on Drug Use and Health:Volume 1. Summary of National Findings 2010, Substance Abuse and Mental Health Services Administration, Rockville, MD.
74. U.S. Department of Health & Human Services Health Resources and Services Adminstration Data Warehouse (HRSA) - Report Tool, Health Care Service Delivery Sites Retrieved March 1, 2013, from. http://datawarehouse.hrsa.gov/.
75. U.S. Drug Enforcement Administration The System to Retrieve Information from Drug Evidence (STRIDE) database Retrieved May 19, 2014, from. http://www.justice.gov/dea/resource-center/stride-data.shtml.
76. Volkow N.D. NIDA at 30: Committed to scientific solutions for drug addiction problems 2004, 19. NIDA Notes, (Retrieved January 15, 2007, from http://www.drugabuse.gov/NIDA_notes/NNvol19N1/DirRep).
77. Watson S.D. Medicaid physician participation: patients, poverty, and physician self-interest. American Journal of Law & Medicine 1995, 21(2-3):191-220.